Standard BioTools Files Q3 2024 10-Q

TL;DR

Standard BioTools 10-Q filed. Q3 2024 numbers are in.

AI Summary

Standard BioTools Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Fluidigm Corp, is involved in laboratory analytical instruments. Key financial data and operational details for the third quarter of 2024 are presented in this filing.

Why It Matters

This filing provides investors and analysts with the latest financial performance and operational updates for Standard BioTools Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a public company filing a quarterly report, there are inherent risks related to financial performance, market conditions, and regulatory compliance.

Key Numbers

• Q3 2024 — Quarterly Period (Reporting period for the 10-Q filing.)
• 2024-09-30 — Reporting Date (The end date for the financial information presented.)
• 2024-11-06 — Filing Date (The date the report was officially submitted to the SEC.)

Key Players & Entities

• STANDARD BIOTOOLS INC. (company) — Filer
• FLUIDIGM CORP (company) — Former Company Name
• 2024-09-30 (date) — Reporting Period End Date
• 2024-11-06 (date) — Filing Date
• SOUTH SAN FRANCISCO, CA (location) — Business Address City and State

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share LAB The Nasdaq

Filing Documents

• lab-20240930.htm (10-Q) — 3033KB
• lab-ex31_1.htm (EX-31.1) — 16KB
• lab-ex31_2.htm (EX-31.2) — 16KB
• lab-ex32_1.htm (EX-32.1) — 8KB
• lab-ex32_2.htm (EX-32.2) — 9KB
• img187298662_0.jpg (GRAPHIC) — 178KB
• 0000950170-24-122473.txt ( ) — 13738KB
• lab-20240930.xsd (EX-101.SCH) — 1721KB
• lab-20240930_htm.xml (XML) — 2671KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2024 and 2023 4 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements: 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 40 Item 6. Exhibits 41 EXHIBIT LIST 41

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

F inancial Statements

Item 1. F inancial Statements STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) (Unaudited) September 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 210,647 $ 51,704 Short-term investments 155,683 63,191 Accounts receivable, net 35,317 19,660 Inventory 42,644 20,533 Prepaid expenses and other current assets 9,316 3,127 Total current assets 453,607 158,215 Inventory, non-current 17,949 — Royalty receivable, non-current 3,388 — Property and equipment, net 41,982 24,187 Operating lease right-of-use asset, net 30,264 30,663 Other non-current assets 4,640 2,285 Acquired intangible assets, net 23,367 1,400 Goodwill 106,342 106,317 Total assets $ 681,539 $ 323,067 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 10,926 $ 9,236 Accrued liabilities 31,686 21,019 Operating lease liabilities, current 6,122 4,323 Deferred revenue, current 13,436 11,607 Deferred grant income, current 3,532 3,612 Term loan, current — 5,000 Convertible notes, current 54,913 54,530 Total current liabilities 120,615 109,327 Convertible notes, non-current 299 569 Term loan, non-current — 3,414 Deferred tax liability 841 841 Operating lease liabilities, non-current 28,140 30,374 Deferred revenue, non-current 32,682 3,520 Deferred grant income, non-current 8,119 10,755 Other non-current liabilities 1,510 1,065 Total liabilities 192,206 159,865 Commitments and contingencies (Note 8) Mezzanine equity: Redeemable preferred stock: $ 0.001 par value; zero and 256 shares authorized and issued and outstanding at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of zero and $ 255,559 at September 30, 2024 and December 31, 202

View Full Filing

View this 10-Q filing on SEC EDGAR